Österborg, A., Udvardy, M., Zaritskey, A., Andersson, P., Grosicki, S., Mazur, G., Kaplan, P., Steurer, M., Schuh, A., Montillo, M., Kryachok, I., Middeke, J. M., Kulyaba, Y., Rekhtman, G., Gorczyca, M., Daly, S., Chang, C., Lisby, S., & Gupta, I. (n.d.). phase III, randomized study of ofatumumab versus physicians' choice of therapy and standard versus extended-length ofatumumab in patients with bulky fludarabine-refractory chronic lymphocytic leukemia. Leukemia & lymphoma, 57(9), 2037–2046. http://access.bl.uk/ark:/81055/vdc_100034566536.0x00003e